Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other Working Capital Changes (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Other Working Capital Changes data on record, last reported at $5.4 million in Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 270.13% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $14.5 million, up 73.26%, while the annual FY2025 figure was $14.5 million, 73.26% up from the prior year.
  • Other Working Capital Changes reached $5.4 million in Q4 2025 per SNDX's latest filing, up from $4.4 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $10.8 million in Q2 2025 and bottomed at -$14.6 million in Q4 2021.
  • Average Other Working Capital Changes over 5 years is $672315.8, with a median of $660000.0 recorded in 2021.
  • Peak YoY movement for Other Working Capital Changes: tumbled 3753.3% in 2021, then soared 2226.14% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at -$14.6 million in 2021, then soared by 67.8% to -$4.7 million in 2022, then skyrocketed by 109.76% to $459000.0 in 2023, then crashed by 791.5% to -$3.2 million in 2024, then soared by 270.13% to $5.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were $5.4 million in Q4 2025, $4.4 million in Q3 2025, and $10.8 million in Q2 2025.